New ANDA Cases

Fall 2018

Robins Kaplan GENERICally Speaking: A Hatch-Waxman Litigation Bulletin
Case Name Date Filed Judge Drug Patent No(s).
Teijin Ltd. v. Torrent Pharms. Ltd., 18-0987 (D. Del.) 2-Jul-18 Vacant Judgeship (2017) Uloric® (febuxostat tablets) 7,361,676,
8,372,872,
9,107,912
Dr. Reddy’s Labs. Inc. v. Pozen Inc., IPR2018-01341 (PTAB) 2-Jul-18 N/A Vimovo® (esomeprazole magnesium / naproxen delayed-release tablets) 9,393,208
Boehringer Ingelheim Pharms., Inc. v. Apotex Inc., 18-11350 (D.N.J.) 3-Jul-18 Hon. Michael A. Shipp Gilotrif® (afatinib tablets) 8,426,586
Celgene Corp. v. Amneal Pharms. LLC, 18-11358 (D.N.J.) 3-Jul-18 Hon. Michael A. Shipp Otezla® (apremilast tablets) 6,962,940,
7,427,638,
7,659,302,
7,893,101,
8,455,536, 
9,018,243
Celgene Corp. v. Aurobindo Pharma Ltd., 18-1005 (D. Del.) 6-Jul-18 Hon. Richard G. Andrews Otezla® (apremilast tablets) 6,962,940,
7,208,516,
7,427,638,
7,659,302,
7,893,101,
8,455,536,
8,802,717,
9,018,243,
9,872,854
Cosmo Technologies Ltd. v. Actavis Labs. FL, Inc., 18-1006 (D. Del.) 6-Jul-18 Hon. Leonard P. Stark Uceris® (budesonide extended-release tablets) 9,737,489,
9,592,203
Mylan Pharms. Inc. v. Anacor Pharms., Inc., IPR2018-01358 (PTAB) 6-Jul-18 N/A Kerydin® (tavaborole topical solution) 9,549,938
Mylan Pharms. Inc. v. Anacor Pharms., Inc., IPR2018-01359 (PTAB) 6-Jul-18 N/A Kerydin® (tavaborole topical solution) 9,566,289
Horizon Pharma, Inc. v. Alkem Labs. Ltd., 18-1014 (D. Del.) 9-Jul-18 Hon. Leonard P. Stark Duexis® (ibuprofen / famotidine tablets) 8,067,033,
8,067,451,
8,309,127,
8,318,202,
8,449,910,
8,501,228
Celgene Corp. v. Sandoz, Inc., 18-1764 (D. Col.) 10-Jul-18 Hon. William J. Martinez Otezla® (apremilast tablets) 6,962,940,
7,208,516,
7,427,638,
7,659,302,
7,893,101,
8,455,536,
8,802,717,
9,018,243,
9,872,854
Celgene Corp. v. Lotus Pharm. Co., Ltd., 18-11518 (D.N.J.) 10-Jul-18 Hon. Susan D. Wigenton Revlimid® (lenalidomide capsules) 7,977,357,
8,193,219,
8,431,598
Mylan Pharms. Inc. v. Anacor Pharms., Inc., IPR2018-01360 (PTAB) 10-Jul-18 N/A Kerydin® (tavaborole topical solution) 9,566,290
Mylan Pharms. Inc. v. Anacor Pharms., Inc., IPR2018-01361 (PTAB) 10-Jul-18 N/A Kerydin® (tavaborole topical solution) 9,572,823
Eli Lilly and Co. v. Torrent Pharms. Ltd., 18-11543 (D.N.J.) 11-Jul-18 Hon. William H. Walls Cialis® (tadalafil tablets) 6,943,166
Celgene Corp. v. Pharmascience Inc., 18-11545 (D.N.J.) 11-Jul-18 Hon. Michael A. Shipp Otezla® (apremilast tablets) 6,962,940,
7,427,638,
7,659,302,
7,893,101,
8,455,536,
9,018,243
Celgene Corp. v. Amneal Pharms. LLC, 18-1032 (D. Del.) 12-Jul-18 Hon. Richard G. Andrews Otezla® (apremilast tablets) 6,962,940,
7,427,638,
7,659,302,
7,893,101,
8,455,536,
9,018,243
H. Lundbeck A/S v. Apicore US LLC, 18-1034 (D. Del.) 12-Jul-18 Hon. Leonard P. Stark Trintellix® (vortioxetine hydrobromide tablets) 7,144,884,
8,476,279,
8,722,684,
8,969,355,
9,227,946,
9,861,630
Novartis Pharms. Corp. v. Apotex Inc., 18-1038 (D. Del.) 13-Jul-18 Hon. Leonard P. Stark Gilenya® (fingolimod capsules) 9,187,405
Novartis Pharms. Corp. v. Teva Pharms. USA, Inc., 18-1039 (D. Del.) 13-Jul-18 Hon. Leonard P. Stark Gilenya® (fingolimod capsules) 9,187,405
Novartis Pharms. Corp. v. Sun Pharm. Indus., Ltd., 18-1040 (D. Del.) 13-Jul-18 Hon. Leonard P. Stark Gilenya® (fingolimod capsules) 9,187,405
Mylan Pharms. Inc. v. Biogen MA, Inc., IPR2018-01403 (PTAB) 13-Jul-18 N/A Tecfidera® (dimethyl fumarate delayed-release capsules) 8,399,514
Takeda Pharm. Co. Ltd. v. Zydus Pharms. (USA) Inc., 18-11792 (D.N.J.) 18-Jul-18 Hon. Freda L. Wolfson Prevacid® SoluTab™ (lansoprazole delayed-release orally-disintegrating tablets) 9,901,546
Genzyme Corp. v. Gland Pharma Ltd., 18-1071 (D. Del.) 19-Jul-18 Hon. Kent A. Jordan Mozobil® (plerixafor for injection) RE42,152,
7,897,590,
6,987,102
Eagle Pharms., Inc. v. Hospira, Inc., 18-1074 (D. Del.) 19-Jul-18 Hon. Leonard P. Stark Bendeka® (bendamustine HCl for injection) 9,572,887,
10,010,533,
9,034,908,
9,144,568,
9,597,397,
9,597,398,
9,597,399,
9,000,021,
9,579,384
Perrigo Research & Development Co. v. GlaxoSmithKline Consumer Healthcare, L.P., 18-11835 (D.N.J.) 29-Jul-18 Hon. Brian R. Martinotti Nicorette® (nicotine polacrilex lozenge) 8,501,164,
8,940,772
Adare Pharms., Inc. v. Teva Pharms. Int’l GMBH, 18-1079 (D. Del.) 20-Jul-18 Hon. Mitchell S. Goldberg Amrix® (cyclobenzaprine HCl extended-release capsules) 9,399,025,
9,375,410
Mallinckrodt Hospital Products IP Ltd. v. B. Braun Medical Inc., 18-1090 (D. Del.) 24-Jul-18 Hon. Leonard P. Stark Ofirmev® (acetaminophen for injection) 9,987,238
Osi Pharms., LLC v. Shilpa Medicare Ltd., 18-1096 (D. Del.) 25-Jul-18 Hon. Gregory M. Sleet Tarceva® (erlotinib HCl tablets) 6,900,221
AstraZeneca Pharms. LP v. Accord Healthcare, Inc., 18-12051 (D.N.J.) 25-Jul-18 Hon. Renee Marie Bumb Faslodex® (fulvestrant for injection) 6,774,122,
7,456,160,
8,329,680,
8,466,139
Shire-NPS Pharms., Inc. v. Par Pharm. Cos., Inc., 18-1115 (D. Del.) 28-Jul-18 Hon. Richard G. Andrews Gattex® (teduglutide for injection) 9,968,655,
9,968,656,
9,968,658,
9,974,835,
9,974,837,
9,981,014,
9,981,016,
9,987,334
Santen Pharm. Co. Ltd., Micro Labs Ltd., 18-12333 (D.N.J.) Aug. 1, 2018 Hon. Brian R. Martinotti Zioptan® (tafluprost ophthalmic solution) 9,999,593
Eli Lilly and Co. v. Umedica Labs. Pvt., Ltd., 18-12385 (D.N.J.) Aug. 2, 2018 Hon. William H. Walls Cialis® (tadalafil tablets) 6,943,166
Neptune Generics, LLC v. Corcept Therapeutics, Inc., IPR2018-01494 (PTAB) Aug. 2, 2018 N/A Korlym® (mifepristone tablets) 8,921,348
Dr. Reddy’s Labs., Inc. v. Celgene Corp., IPR2018-01504 (PTAB) Aug. 3, 2018 N/A Revlimid® (lenalidomide capsules) 9,056,120
Dr. Reddy’s Labs., Inc. v. Celgene Corp., IPR2018-01507 (PTAB) Aug. 3, 2018 N/A Revlimid® (lenalidomide capsules) 8,404,717
Dr. Reddy’s Labs., Inc. v. Celgene Corp., IPR2018-01509 (PTAB) Aug. 3, 2018 N/A Revlimid® (lenalidomide capsules) 7,189,740
Fresenius Kabi USA, LLC v. Custopharm, Inc., 18-0665 (W.D. Tex.) Aug. 6, 2018 Hon. Lee Yeakel Naropin® (ropivacaine HCl for injection) 8,118,802,
8,162,915
Taro Pharms. U.S.A., Inc. v. Glenmark Pharms. Ltd., 18-12569 (D.N.J.) Aug. 8, 2018 Hon. John Michael Vazquez Topicort® (desoximetasone topical spray) 8,277,780,
8,715,624
Horizon Therapeutics, LLC v. Par Pharm., Inc., 18-1224 (D. Del.) Aug. 10, 2018 Hon. Richard G. Andrews Ravicti® (glycerol phenylbutyrate oral liquid) 8,642,012
Allergan, Inc. v. Saptalis Pharms., LLC, 18-1231 (D. Del.) Aug. 10, 2018 Hon. Leonard P. Stark Restasis® (cyclosporine ophthalmic emulsion) 8,633,162,
8,642,556
AstraZeneca LP v. Hisun Pharm. (Hangzhou) Co., Ltd., 18-1232 (D. Del.) Aug. 10, 2018 Hon. Richard G. Andrews Brilinta® (ticagrelor tablets) RE46,276,
7,250,419,
7,265,124
Boehringer Ingelheim Pharms., Inc. v. Lupin Atlantis Holdings SA, 18-12663 (D.N.J.) Aug. 10, 2018 Hon. Brian R. Martinotti Spiriva® HandiHaler® (tiotropium bromide inhalation powder) 7,070,800,
7,694,676
Athenex Pharma Solutions, LLC v. Par Pharm., Inc., 18-0896 (W.D.N.Y.) Aug. 13, 2018 Hon. Geoffrey Crawford Vasostrict® (vasopressin injection) 9,375,478,
9,687,526,
9,744,209,
9,744,239,
9,750,785,
9,937,223
Shionogi Inc. v. Zydus Pharms. (USA) Inc., 18-12898 (D.N.J.) Aug. 16, 2018 Hon. Brian R. Martinotti Fortamet® (metformin HCl extended-release tablets) 6,790,459,
6,866,866
Par Pharm., Inc. v. Horizon Therapeutics, LLC, IPR2018-01550 (PTAB) Aug. 21, 2018 N/A Ravicti® (glycerol phenylbutyrate oral liquid) 9,561,197
Valeant Pharms. Int’l v. Actavis Labs. FL., Inc., 18-1288 (D. Del.) Aug. 22, 2018 Hon. Leonard P. Stark Uceris® (budesonide extended-release tablets) 10,052,286
Biofrontera Inc. v. Dusa Pharms., Inc., IPR2018-01585 (PTAB) Aug. 22, 2018 N/A Levulan® (aminolevulinic acid HCl topical solution) 8,216,289
Biofrontera Inc. v. Dusa Pharms., Inc., IPR2018-01585 (PTAB) Aug. 22, 2018 N/A Levulan® (aminolevulinic acid HCl topical solution) 9,723,991
Insys Therapeutics, Inc. v. Teva Pharms. USA, Inc., 18-1308 (D. Del.) Aug. 23, 2018 Hon. Colm F. Connolly Subsys® (fentanyl sublingual spray) 8,486,972,
8,486,973,
8,835,459,
8,835,460,
9,241,935,
9,289,387,
9,642,797,
9,642,844
Biogen Int’l Gmbh v. Windlas Healthcare, Pvt. Ltd., 18-1361 (D. Del.) Aug. 31, 2018 Hon. Leonard P. Stark Tecfidera® (dimethyl fumarate delayed-release capsules) 6,509,376,
7,320,999
Celgene Corp. v. West-ward Pharms. Int’l Ltd., 18-13477 (D.N.J.) Aug. 31, 2018 Hon. Susan D. Wigenton Thalomid® (thalidomide capsules) 6,315,720,
6,561,977,
6,755,784,
6,869,399,
7,141,018,
7,230,012,
7,959,566,
8,315,886,
8,626,531
Sumitomo Dainippon Pharma Co., Ltd. v. Piramal Healthcare UK Ltd., 18-13478 (D.N.J.) Aug. 31, 2018 Hon. Stanley R. Chesler Latuda® (lurasidone HCl tablets) 9,815,827,
9,907,794
Symed Labs Ltd. v. Amneal Pharms. LLC, 18-13628 (D.N.J.) Sept. 6, 2018 Hon. Claire C. Cecchi linezolid tablets 7,351,824,
7,429,661
Valeant Pharms. North America LLC v. Zydus Pharms. (USA) Inc., 18-13635 (D.N.J.) Sept. 6, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Amgen Inc. v. Emcure Pharms. Ltd., 18-1393 (D. Del.) Sept. 7, 2018 Hon. Mitchell S. Goldberg Sensipar® (cinacalcet tablets) 9,375,405
Biodelivery Sciences Int’l, Inc. v. Alvogen Pb Research & Development LLC, 18-1395 (D. Del.) Sept. 7, 2018 Hon. Colm F. Connolly Belbuca® (buprenorphine buccal film) 8,147,866,
9,655,843,
9,901,539
Valeant Pharms. North America LLC v. Aurobindo Pharma USA Inc., 18-13693 (D.N.J.) Sept. 7, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Solaris Pharma Corp., 18-13695 (D.N.J.) Sept. 7, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Strides Pharma Inc., 18-13696 (D.N.J.) Sept. 7, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Lupin Ltd., 18-13700 (D.N.J.) Sept. 7, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Par Pharm., Inc., 18-13701 (D.N.J.) Sept. 7, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Par Pharm., Inc., 18-8221 (S.D.N.Y.) Sept. 10, 2018 Hon. Edgardo Ramos Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01670 (PTAB) Sept. 10, 2018 N/A Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) 8,679,069
Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01675 (PTAB) Sept. 10, 2018 N/A Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) 8,603,044
Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01676 (PTAB) Sept. 10, 2018 N/A Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) 8,603,044
Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01677 (PTAB) Sept. 10, 2018 N/A Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) 8,992,486
Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01678 (PTAB) Sept. 10, 2018 N/A Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) 8,992,486
Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01679 (PTAB) Sept. 10, 2018 N/A Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) 8,992,486
Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01680 (PTAB) Sept. 10, 2018 N/A Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) 9,526,844
Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01682 (PTAB) Sept. 10, 2018 N/A Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) 9,526,844
Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01684 (PTAB) Sept. 10, 2018 N/A Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) 9,604,008
Mylan Pharms. Inc. v. Sanofi-Aventis Deutschland Gmbh, IPR2018-01696 (PTAB) Sept. 10, 2018 N/A Lantus® SoloStar® (insulin glargine recombinant for injection), Apidra® SoloStar® (insulin glulisine recombinant for injection), Toujeo® (Insulin glargine recombinant subcutaneous solution), Soliqua® (insulin glargine / lixisenatide subcutaneous solution), Admelog® Solostar® (insulin lispro for injection) 9,526,844
Sumitomo Dainippon Pharma Co., Ltd. v. Macleods Pharms. Ltd., 18-13833 (D.N.J.) Sept. 12, 2018 Hon. Stanley R. Chesler Latuda® (lurasidone HCl tablets) 9,815,827,
9,907,794
Alvogen Pine Brook LLC v. Celgene Corp., IPR2018-01714 (PTAB) Sept. 12, 2018 N/A Revlimid® (lenalidomide capsules) 7,968,569
Valeant Pharms. North America LLC v. Alkem Labs. Ltd., 18-13905 (D.N.J.) Sept. 14, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Alkem Labs. Ltd., 18-13954 (D.N.J.) Sept. 17, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Duke University v. Akorn, Inc., 18-14035 (D.N.J.) Sept. 19, 2018 Hon. Brian R. Martinotti Latisse® (bimatoprost ophthalmic solution) 9,579,270
Allergan, Inc. v. Amneal Pharms. LLC, 18-1457 (D. Del.) Sept. 20, 2018 Hon. Leonard P. Stark Restasis® (cyclosporine ophthalmic emulsion) 8,633,162,
8,642,556
Eagle Pharms., Inc. v. Slayback Pharma LLC, 18-1459 (D. Del.) Sept. 20, 2018 Hon. Colm F. Connolly Bendamustine HCl Injection) 8,609,707,
9,265,831,
9,572,796,
9,572,797,
10,010,533
Celgene Corp. v. Hetero Labs Ltd., 18-14111 (D.N.J.) Sept. 20, 2018 Hon. Esther Salas Pomalyst® (pomalidomide capsules) 9,993,467
Bayer Healthcare LLC v. Apotex Inc., 18-1465 (D. Del.) Sept. 21, 2018 Hon. Leonard P. Stark Stivarga® (regorafenib tablets) 9,957,232
Valeant Pharms. North America LLC v. Acrux DDS Pty Ltd., 18-14194 (D.N.J.) Sept. 21, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Apotex Inc., 18-14202 (D.N.J.) Sept. 21, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Macleods Pharms. Ltd., 18-14204 (D.N.J.) Sept. 21, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Perrigo Pharma Int’l DAC, 18-14207 (D.N.J.) Sept. 21, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Slayback Pharma, LLC, 18-14208 (D.N.J.) Sept. 21, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Teva Pharms. USA, Inc., 18-14209 (D.N.J.) Sept. 21, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Cipla Ltd., 18-14225 (D.N.J.) Sept. 24, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. KVK-Tech, Inc., Ltd., 18-14298 (D.N.J.) Sept. 26, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. Mylan Pharms. Inc., 18-14305 (D.N.J.) Sept. 26, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Adamis Pharms. Corp. v. Belcher Pharms., LLC, 18-2379 (M.D. Fla.) Sept. 26, 2018 Hon. William F. Jung Symjepi® (epinephrine for injection) 9,283,197,
10,004,700
Celgene Corp. v. Teva Pharms USA, Inc., 18-14366 (D.N.J.) Sept. 27, 2018 Hon. Esther Salas Pomalyst® (pomalidomide capsules) 9,993,467
Valeant Pharms. North America LLC v. Mylan Pharms. Inc., 18-0184 (N.D.W.V.) Sept. 26, 2018 Hon. Irene M. Keeley Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Valeant Pharms. North America LLC v. KVK-Tech, Inc., Ltd., 18-4195 (E.D. Pa.) Sept. 27, 2018 Hon. Paul S. Diamond Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Alembic Pharms. Ltd. v. GlaxoSmithKline LLC, 18-1513 (D. Del.) Sept. 28, 2018 Hon. Richard G. Andrews Lamictal® XR (lamotrigine extended-release tablets) 8,637,512,
9,144,547
Valeant Pharms. North America LLC v. Amneal Pharms. LLC, 18-14468 (D.N.J.) Sept. 28, 2018 Hon. Peter G. Sheridan Jublia® (efinaconazole topical solution) 7,214,506,
8,039,494,
8,486,978,
9,302,009,
9,566,272,
9,662,394,
9,861,698,
9,877,955
Back to Top